Gilead Lowering HCV Drug List Prices With Authorized Generics
Approach has been endorsed by Express Scripts as more workable solution than trying to cut list prices for drugs already on the market.
You may also be interested in...
Gilead Says Sluggish Yescarta Business Will Continue To Fluctuate
The CAR-T therapy’s sales declined 2% from the previous quarter, although EU sales are growing briskly. The HIV franchise posted its best quarter ever, but the company’s overall financial performance was flat.
A Case For List Price Cuts? Study Highlights Reduced 340B Liability For Hep C Drugs
Lower list prices for Epclusa, Harvoni, and Zepatier might actually boost revenue by reducing 340B discounts, but rebate-eschewing dynamic may not expand beyond them because of different exposures to 340B in other classes – and the pending HHS rebate rule.
What Will Happen When Rebates Go Away? Look At Authorized Generics
Recent launches by Lilly, Amgen and Gilead suggest list prices may decrease with the HHS proposal to disrupt the rebate system, but not as low as current net prices after rebates, according to pharmacy benefit experts.